FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development: GlobalData EP News Bureau Sep 1, 2025 GlobalData notes FDA’s acceptance of VCTE as a surrogate endpoint may reduce reliance on biopsies, ease patient enrolment, and…
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest… EP News Bureau Aug 11, 2025 Phase III UP-AA trial data show higher response rates than current JAK inhibitors, positioning AbbVie’s upadacitinib as a…
